Group 5: SCT rats þ FF 0.18 mg/kg/d þ 72-h wash-out period; Group 6: SCT rats þ FF 0.12 mg/kg/d þ 72-h wash-out period. SCT was performed at T10. FF was continuously administered from post-op day 1. RT-PCR and immunofluorescence staining was done to investigate the presence and distribution of the receptors in the bladder. The variation of expression of the muscarinic receptors (M1 to M5) between each study group was evaluated by qPCR with specific sets of primers. Comparisons between groups were conducted using a Single Factor ANOVA and two-way T-tests.
Reference: 1. Biardeau X, et al. Early fesoterodine fumarate administration prevents neurogenic detrusor overactivity in a spinal cord transected rat model. PLoS One. 2017 Jan 6;12(1).
Source of Funding: Mitacs Canada and Pfizer Canada

MP62-20 LOCALIZATION AND EXPRESSION OF EXTRACELLULAR MATRIX COMPONENTS VERSICAN AND HYALURONAN IN URETHRAL AND VAGINAL TISSUES IN HUMAN SPECIMENS AND IN RAT MODEL OF URINARY INCONTINENCE
Ingrid Harten, Stephen Evanko, Seattle, WA; Jay Choe, San Diego, CA; Eugene Lee, Hayward, CA; Marika Bogdani, Thomas Wight, Una Lee*, Seattle, WA INTRODUCTION AND OBJECTIVES: Abnormal extracellular matrix (ECM) has been correlated with stress urinary incontinence (SUI). ECM components versican (VC) and hyaluronan (HA) play key roles in regulating tissue inflammation and maintaining connective tissue homeostasis. The objective of this study is to analyze the localization and expression of ECM components VC and HA in urethral and vaginal tissues in human clinical specimens and in a rat model of urinary incontinence.
METHODS: Nulliparous Sprague-Dawley female rats underwent vaginal distension (VD), a rodent model of SUI, or a sham procedure. Tissues were harvested from 6 rats per group at days 1, 4, and 21 for immunohistochemistry and RNA expression analysis of ECM components. Urethral and vaginal samples from female patients with and without SUI were also examined.
RESULTS: High intensity staining of VC was found in both sham and VD animals 1 day after surgery. This elevation persisted at day 4 in VD compared to sham, with concurrent reduced mRNA expression of VC degrading enzymes ADAMST 5 and 9 (Figure 1) . Abundance of HA was not different between VD and sham, however mRNA expression of the HA synthase Has2 was significantly reduced in VD at day 4. Abundant versican staining was found in 60% of patient samples with SUI, which was strongest in regions of disrupted elastin.
CONCLUSIONS: Reduction of VC degrading enzymes and HA synthases at day 4 post surgery indicate a potential delay in ECM turnover associated with SUI. Abundant VC is associated with inflammation and elastin fiber network disruption, warranting further investigation to determine its role in the pathogenesis of SUI. The available data in urological literature regarding the role of n-3 PUFAs in the field of BC chemo-prevention are scarce and conflicting. The present work aims to test the chemo-preventative effects of n-3 PUFAs against BC induction in a rat model and the potential anti-neoplastic mechanisms of the drug.
METHODS: Ninety male Fisher rats were divided into 3 groups during a 22-week protocol: group 1 (control), group 2 (Placeboþ Nbutyl-N-4-hydroxybutyl nitrosamine (BBN) for induction of BC ) and group 3 received n-3 PUFAs at a daily dose of 1,200 mg/kg/day þ BBN (figure 1). At the end, blood samples and bladder tissues were collected and checked for the presence of malignancy, markers of angiogenesis (CD34 expression and VEGF relative gene expression), inflammation (IL-6), proliferation (KI-67 expressions), redox status (serum MDA) and epigenetic control (miRNA-145 level). Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e895
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